Horizontal neck lines.
Conditions
Interventions
Intervention 1: Control group: In 10 patients, Botulinum toxin (Dysport, IPSEN Company ) injection will be performed in the baseline visit according to the following protocol: 1 vial of Botox Dysport
Sponsors
Tehran University of Medical Sciences
IBSA Institue Biochemique SA
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Adults over 18 years and under 70 years Signing a voluntary agreement WSRS (Wrinkle Severity Rating Scale) between 4 - 2 They do not want to have a surgical procedure Patients who are not candidates for surgery
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding Neuromuscular diseases such as myasthenia gravis• Hypersensitivity to Botox or human albumin• Uncontrolled systemic disease Infection, scarring, abnormality at the injection site History of Botox injection or lower face filler in the last 12 months Patients treated with aspirin, immunosuppressants, narcotics, antiDepressants and corticosteroids in the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Wrinkle severity rating scale (WSRS). Timepoint: The first visit and 6 months after Dysport injection and the second time filler. Method of measurement: Score based on the severity of wrinkles by comparing photography and dermoscopy before and after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin hydration. Timepoint: Baseline visit and 6 months after the second filler injection in one group and one time of receiving dysport in the second group. Method of measurement: probe of the MP bolagen multi-adapter device(corporatereg number 5562201656) to measure hydration of the skin.;Skin elasticity. Timepoint: Baseline visit and 6 months after the second filler injection in one group and one time of receiving dysport in the second group. Method of measurement: probe of the MP bolagen multi-adapter device(corporatereg number 5562201656).;Water loss from the surface of the epidermis. Timepoint: Baseline visit and 6 months after the second filler injection in one group and one time of receiving dysport in the second group. Method of measurement: probe of the MP bolagen multi-adapter device(corporatereg number 5562201656).;Pain during filler injection. Timepoint: During filler injection (two weeks after the first visit and one month after the second visit). Method of measurement: Patient self-expression form.;Dermis and epidermis density. Timepoint: Baseline visit and 6 months after the second filler injection in one group and one time of receiving dysport in the second group. Method of measurement: Neck sonography.;Dermis and epidermis thickness. Timepoint: Baseline visit and 6 months after the second filler injection in one group and one time of receiving dysport in the second group. Method of measurement: Neck sonography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAsma Jabbari
Tehran University of Medical Sciences
Outcome results
None listed